Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner

J Immunol. 2018 Apr 1;200(7):2509-2510. doi: 10.4049/jimmunol.1800167. Epub 2018 Feb 23.
No abstract available

Publication types

  • Published Erratum